194 related articles for article (PubMed ID: 37954266)
1. Identification and validation of a novel signature based on T cell marker genes to predict prognosis, immunotherapy response and chemotherapy sensitivity in head and neck squamous carcinoma by integrated analysis of single-cell and bulk RNA-sequencing.
Zhou C; Deng H; Fang Y; Wei Z; Shen Y; Qiu S; Ye D; Shen Z; Shen Y
Heliyon; 2023 Nov; 9(11):e21381. PubMed ID: 37954266
[TBL] [Abstract][Full Text] [Related]
2. Telomere maintenance genes-derived prognosis signature characterizes immune landscape and predicts prognosis of head and neck squamous cell carcinoma.
Zou J; Chu S; Bao Q; Zhang Y
Medicine (Baltimore); 2023 Aug; 102(31):e34586. PubMed ID: 37543795
[TBL] [Abstract][Full Text] [Related]
3. Integrated single-cell and bulk RNA sequencing analyses reveal a prognostic signature of cancer-associated fibroblasts in head and neck squamous cell carcinoma.
Yang Y; Ma B; Han L; Xu W; Du X; Wei W; Liao T; Ji Q; Qu N; Wang Y
Front Genet; 2022; 13():1028469. PubMed ID: 36568368
[No Abstract] [Full Text] [Related]
4. Identification and verification of eight cancer-associated fibroblasts related genes as a prognostic signature for head and neck squamous cell carcinoma.
Dong L; Sun Q; Song F; Song X; Lu C; Li Y; Song X
Heliyon; 2023 Mar; 9(3):e14003. PubMed ID: 36938461
[TBL] [Abstract][Full Text] [Related]
5. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Shi Y; Huang J; Hu Y; Shen Y
BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
[TBL] [Abstract][Full Text] [Related]
6. Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma.
Lin C; Chen Y; Pan J; Lu Q; Ji P; Lin S; Liu C; Lin S; Li M; Zong J
BMC Genomics; 2023 Apr; 24(1):221. PubMed ID: 37106442
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma.
Shi X; Dong A; Jia X; Zheng G; Wang N; Wang Y; Yang C; Lu J; Yang Y
Front Immunol; 2022; 13():992990. PubMed ID: 36311764
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
Zhang F; Liu Y; Yang Y; Yang K
BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
[TBL] [Abstract][Full Text] [Related]
10. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
11. A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma.
Zhou C; Shen Y; Jin Y; Shen Z; Ye D; Shen Y; Deng H
Cancer Med; 2022 Dec; 11(24):5097-5112. PubMed ID: 35567376
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
[TBL] [Abstract][Full Text] [Related]
13. A novel immune signature predicts immunotherapy responsiveness and reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma.
Wang Q; Zhao Y; Wang F; Tan G
Front Genet; 2022; 13():1051051. PubMed ID: 36437964
[No Abstract] [Full Text] [Related]
14. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
15. A Signature of N
Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X
Front Immunol; 2022; 13():809872. PubMed ID: 35185897
[TBL] [Abstract][Full Text] [Related]
16. A novel cuproptosis-related lncRNA prognostic signature for predicting treatment and immune environment of head and neck squamous cell carcinoma.
Huan C; Gao J
Math Biosci Eng; 2022 Aug; 19(12):12127-12145. PubMed ID: 36653989
[TBL] [Abstract][Full Text] [Related]
17. Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma.
Zheng H; Li Y; Zhao Y; Jiang A
Sci Rep; 2023 Mar; 13(1):3684. PubMed ID: 36878969
[TBL] [Abstract][Full Text] [Related]
18. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular classification and gene signature for predicting prognosis and immunotherapy response in HNSCC using cell differentiation trajectories.
Yin J; Zheng S; He X; Huang Y; Hu L; Qin F; Zhong L; Li S; Hu W; Zhu J
Sci Rep; 2022 Nov; 12(1):20404. PubMed ID: 36437265
[TBL] [Abstract][Full Text] [Related]
20. Nine-gene signature and nomogram for predicting survival in patients with head and neck squamous cell carcinoma.
Yang F; Zhou LQ; Yang HW; Wang YJ
Front Genet; 2022; 13():927614. PubMed ID: 36092911
[No Abstract] [Full Text] [Related]
[Next] [New Search]
